Loading...
XSHG600200
Market cap912mUSD
Dec 26, Last price  
9.37CNY
1D
0.64%
1Q
-2.29%
Jan 2017
-51.48%
Name

JiangSu WuZhong Pharmaceutical Development Co Ltd

Chart & Performance

D1W1MN
XSHG:600200 chart
P/E
—
P/S
2.97
EPS
—
Div Yield, %
1.02%
Shrs. gr., 5y
0.15%
Rev. gr., 5y
5.65%
Revenues
2.24b
+10.55%
1,174,248,1961,431,099,7901,848,411,6712,381,892,2492,491,786,1762,308,576,7753,384,172,2883,875,287,5123,722,974,6843,875,301,4543,066,487,2882,928,356,2223,989,290,7862,960,487,7671,701,627,6072,109,850,6521,871,736,6701,775,450,7102,026,232,8362,239,962,539
Net income
-72m
54,579,94435,030,48615,756,73206,850,04314,566,79329,301,59430,866,24546,837,11750,537,21140,849,69449,112,99671,996,134133,105,250064,533,748022,716,2820-71,945,211
CFO
-204m
L
170,895,80355,012,72053,802,299029,756,560174,232,67300438,417,008229,889,693041,110,038693,453,447249,141,522334,027,63200447,643,66756,273,913-203,678,316
Dividend
Jun 15, 20180.056 CNY/sh
Earnings
May 16, 2025

Profile

JiangSu WuZhong Pharmaceutical Development Co., Ltd., together with its subsidiaries, engages in pharmaceutical, real estate, and chemical businesses in China. It develops, produces, and sells anti-infective, digestive system, cardiovascular, cerebrovascular, antiviral, vitamin, and hemostatic drugs; and immunomodulations, including biopharmaceuticals, chemical drugs, and modern Chinese medicines. The company offers its products in various forms, such as infusion solutions, water and powder injections, capsules, granules, tablets, emulsions, and oral liquids. It also engages in the research, development, production, and sale of dyes and dye intermediates; and the fields of commercial housing and affordable housing development. The company was founded in 1994 and is based in Suzhou, China.
URL
http://www.600200.com/
IPO date
Apr 01, 1999
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
2,239,963
10.55%
2,026,233
14.12%
1,775,451
-5.14%
Cost of revenue
2,157,751
1,962,796
1,729,694
Unusual Expense (Income)
NOPBT
82,212
63,436
45,756
NOPBT Margin
3.67%
3.13%
2.58%
Operating Taxes
3,263
2,827
18,603
Tax Rate
3.97%
4.46%
40.66%
NOPAT
78,948
60,610
27,153
Net income
(71,945)
 
22,716
 
Dividends
(67,858)
Dividend yield
1.15%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
1,583,106
1,402,685
1,179,186
Long-term debt
154,260
219,042
168,373
Deferred revenue
4,504
5,306
7,210
Other long-term liabilities
36,747
54,092
4,530
Net debt
(673,298)
(588,568)
(408,081)
Cash flow
Cash from operating activities
(203,678)
56,274
447,644
CAPEX
(82,584)
Cash from investing activities
358,901
61,336
43,271
Cash from financing activities
123,849
114,737
FCF
341,396
318,244
465,440
Balance
Cash
1,712,778
1,477,051
1,130,944
Long term investments
697,886
733,244
624,695
Excess cash
2,298,666
2,108,984
1,666,867
Stockholders' equity
241,188
885,186
876,047
Invested Capital
3,280,825
2,529,979
2,331,159
ROIC
2.72%
2.49%
1.17%
ROCE
2.33%
1.85%
1.42%
EV
Common stock shares outstanding
719,452
712,324
704,560
Price
8.22
7.45%
7.65
-10.74%
8.57
59.29%
Market cap
5,913,896
8.53%
5,449,277
-9.75%
6,038,075
59.29%
EV
5,258,028
4,880,590
5,651,908
EBITDA
128,100
111,071
95,508
EV/EBITDA
41.05
43.94
59.18
Interest
76,344
74,600
64,674
Interest/NOPBT
92.86%
117.60%
141.34%